HIV-associated lipodystrophy.
The HIV associated lipodystrophy syndrome is characterized by fat loss from the periphery, fat accumulation in the abdominal, dorsocervical regions and breasts, and hyperlipidaemia, insulin resistance and lactic acidaemia. Although several mechanisms have been proposed to explain these abnormalities, the exact aetiology of the condition remains unclear and will likely prove to be complex. The principal clinical concerns that arise from this disorder are possible increased risks of premature atherosclerosis and cardiovascular disease. A variety of therapeutic interventions, designed to limit these risks, are under evaluation.
Mallon
P W
PW
National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Australia. pmallon@nchecr.unsw.edu.au
Cooper
D A
DA
Carr
A
A
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001161:Arteriosclerosis / Q000503:physiopathology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000503:physiopathology; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000139:chemically induced* / Q000503:physiopathology / Q000821:virology*